Septerna, Inc. Common Stock (SEPN NASDAQ) stock market data APIs
$11.7743
-0.15(-1.3%)
as of July 11, 2025
Try our APIs with
free plan!
Septerna, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Prev. Close
11.7743
Open
11.6212
High
11.9381
Low
11.5156
52 wk Range
4.17-28.99
Market Cap
444 M
Shares Outstanding
44 558 K
Revenue
977 K
EPS
-0.49
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Septerna, Inc. Common Stock data using free add-ons & libraries
Get Septerna, Inc. Common Stock Fundamental Data
Septerna, Inc. Common Stock Fundamental data includes:
- Net Revenue: 977 K
- EBITDA: -89 761 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -0.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Septerna, Inc. Common Stock News
New
The Implied Analyst 12-Month Target For AVSC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, an...
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Ora...
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the anno...
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license agreement with Danish pharma company, Novo Nordisk NVO, for developing and com...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
